Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for … – PR Newswire (press release)
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for …PR Newswire (press release)The primary objective of the Phase 1b portion of the study is to characterize the safety and establish the dos… Continue reading
